Silo Pharma Reports Q1 2025 Financial Results with Increased Net Loss and Operating Expenses

Silo Pharma, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $1,031,437, or $0.23 per share, compared to a net loss of $801,667, or $0.28 per share, in the same period last year. The company generated $18,026 in revenue, consistent with the previous year, primarily from license fees related to its agreements with Aikido Pharma Inc. and the University of Maryland, Baltimore. The cost of revenues remained unchanged at $1,460, resulting in a gross profit of $16,566 for both periods.

Total operating expenses increased significantly to $1,110,687 from $896,079 year-over-year, driven largely by an 86.6% rise in research and development expenses, which reached $593,962. This increase reflects the company's ongoing investment in its product candidates, including its lead program targeting PTSD and stress-induced anxiety disorders. Compensation expenses also saw a slight increase, while professional fees decreased due to reduced consulting and legal costs.

Silo Pharma's total assets decreased to $5,899,969 as of March 31, 2025, down from $7,411,840 at the end of 2024. The decline was attributed to a reduction in cash and short-term investments, which fell to $3,136,880 and $2,314,550, respectively. Current liabilities also decreased, leading to a working capital of $4,418,858, down from $5,455,483 at the end of the previous year. The company reported cash used in operating activities of $1,640,300, a significant increase from $838,179 in the prior year, indicating heightened operational expenditures.

Strategically, Silo Pharma is focused on advancing its product pipeline, which includes therapies for PTSD, fibromyalgia, Alzheimer's disease, and multiple sclerosis. The company has entered into various licensing agreements, including a recent exclusive license with Columbia University for the development of its intranasal drug candidate, SPC-15. The company plans to continue its research and development efforts, with expectations of increased costs associated with clinical trials and product development.

Looking ahead, Silo Pharma believes it has sufficient cash and liquid short-term investments to meet its obligations for at least the next twelve months. The company is actively pursuing opportunities to expand its product offerings and enhance its market position in the biopharmaceutical sector, particularly in the area of psychedelic therapies for mental health conditions.